Treatment with the dipeptidyl peptidase-4 inhibitor, anagliptin, or with the -glucosidase inhibitor, miglitol, reduced the oral sucrose load-inducible expression of interleukin (IL)-1, IL-18, tumor necrosis factor-, S100a8, S100a9, S100a11, IL-1R2, IL-1Rn and tumor necrosis factor receptor 2 genes in peripheral leukocytes of Otsuka Long-Evans Tokushima fatty (OLETF) rats at the stage of impaired glucose tolerance. Inhibiting postprandial hyperglycemia reduced the expression of genes related to inflammation in peripheral leukocytes of OLETF rats.
Many recent studies have demonstrated that patients with type 2 diabetes had a higher subsequent incidence of such arteriosclerosis-related problems as cardiovascular disease (CVD). In particular, the development of CVD in subjects with impaired glucose tolerance (IGT) as well as type 2 diabetic patients was related to the elevation of postprandial hyperglycemia. Epidemiological studies like the DECODE and Funagata trials have reported that IGT, but not impaired fasting glucose, was strongly and positively associated with the subsequent incidence of CVD. 1, 2) In addition, the STOP-NIDDM study on patients with IGT has demonstrated that inhibiting postprandial hyperglycemia by the -glucosidase inhibitor, acarbose, reduced the development of type 2 diabetes and CVD. 3, 4) The inhibition of postprandial hyperglycemia in patients with IGT and type 2 diabetes is therefore important for suppressing associated complications, in particular CVD. Recent studies have shown that such inflammatory cytokines as interleukin (IL)-1, IL-6, IL-12, IL-18 and tumor necrosis factor (TNF)-secreted from activated leukocytes, including neutrophils, monocytes and macrophages, were linked to diabetic complications. It has already been reported that insulin resistance and hyperglycemia in patients with IGT and type 2 diabetes were associated with elevated plasma levels of IL-1, IL-6, IL-12, IL-18 and TNF-proteins. [5] [6] [7] [8] [9] [10] These inflammatory cytokines activate macrophages/monocytes and induce the infiltration of macrophages into many tissues, resulting in the development and progression of arteriosclerosis, insulin resistance, apoptosis of islet -cells, nephropathy and other complications. 8) One of our previous studies has shown that intermittent treatment with miglitol, an inhibitor of -glucosidases that participate in carbohydrate digestion in the small intestine, 11) reduced the expression of such inflammatory cytokine genes as IL-1, IL-18 and TNF-in peripheral leukocytes of low-dose streptozotocin (STZ)-treated rats with intermittent postprandial hyperglycemia.
12) Such dipeptidyl peptidase-4 (DPP-4) inhibitors, which reduce postprandial hyperglycemia by enhancing gut hormone incretins, as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) have recently been developed. These DPP-4 inhibitors promote insulin secretion by enhancing the incretin concentration in the blood through the inhibition of incretin breakdown. It is most likely that reducing postprandial hyperglycemia by DPP-4 inhibitors would reduce the risk of CVD by repressing inflammatory cytokine expression in peripheral leukocytes. We examined in this study whether either the DPP-4 inhibitor, anagliptin, or miglitol would reduce the expression of the inflammation-related genes in peripheral leukocytes of Otsuka Long-Evans Tokushima fatty (OLETF) rats, which exhibit obesity in addition to the late onset of chronic and slowly progressive hyperinsulinemia, hyperglycemia and hyperlipidemia caused by overeating, 13) at the stage of IGT.
Twenty-four male OLETF rats at 4 weeks of age were obtained from the Otsuka GEN Research Institute (Tokushima, Japan). The rats were raised in individual cages and maintained at a constant temperature (23 AE 2 C) and humidity (55 AE 5%) under a 12-h y To whom correspondence should be addressed. Tel: +81-54-264-5533; Fax: +81-54-264-5565; E-mail: gouda@u-shizuoka-ken.ac.jp Abbreviations: ANCOVA, analysis of covariance; ANOVA, analysis of variance; CVD, cardiovascular disease; DPP-4, dipeptidyl peptidase-4; GIP, glucose-dependent insulinotropic polypeptide; GLP-1, glucagon-like peptide-1; HPRT, hypoxanthine-guanine phosphoribosyltransferase; IGT, impaired glucose tolerance; IL, interleukin; IL-1R, interleukin 1 receptor; IL-1Rn, interleukin 1 receptor antagonist; OLETF, Otsuka Long-Evans Tokushima fatty; RAGE, receptor for advanced glycation endproduct; TNF-, tumor necrosis factor-; TNFR, tumor necrosis factor receptor; SEM, standard error of the mean; STZ, streptozotocin light/dark cycle (lights on: 07:00-19:00). After being fed a standard MF laboratory diet (Oriental Yeast, Tokyo, Japan) for 10 d, all the rats consumed a 40% sucrose solution ad libitum from a water bottle during the period of 6-10 weeks of age. Four weeks after starting administration of the sucrose solution, the rats were given regular water and fed an experimental highcarbohydrate rodent diet until 13 weeks of age. The diet was based on the recommendations of the American Institute of Nutrition (AIN) 14) and contained 20% (w/w) casein, 27.8% corn starch, 27.8% sucrose, 9.5% corn oil, 5% lard, 3.5% AIN93 vitamin mix, 1% AIN93G mineral mix, 5% cellulose, 0.3% L-cysteine and 0.25% choline bitartrate. After confirming that the rats exhibited a sufficient level of IGT, the animals were assigned to one of three groups (n ¼ 8) between which there were no significant differences in the 14-h fasted plasma glucose concentrations ([mean AE standard error of the mean (SEM)], 142:7 AE 1:8 mg/dL), HbA1c (4:8 AE 0:1%) and body weight (453:1 AE 1:2 g). At 13 weeks of age, all rats underwent oral sucrose loading (2 g/kg of body weight as a 40% sucrose solution) either without treatment (control group), with the miglitol -glucosidase inhibitor (0.2 mg/mL), or with the anagliptin DPP-4 inhibitor (3 mg/kg of body weight). Miglitol was included in the sucrose solution, while a dose of 0.6 mg/mL of anagliptin was orally administered 30 min before the sucrose administration. Both anagliptin and miglitol were provided by Sanwa Kagaku Kenkyusho Co. (Mie, Japan). Blood samples were collected from the tail vein by using a capillary containing sodium fluoride and heparin-lithium (Terumo Co., Tokyo, Japan) immediately prior to (0 min) and 15, 30, 60, 90, 120 and 180 min after sucrose administration for glucose measurement, and immediately prior to and 180 min after sucrose administration for RNA extraction. The experimental procedures used in the present study conformed to the guidelines of the Animal Usage Committee of the University of Shizuoka. Plasma glucose was determined by using a Glucose C-II-test kit (Wako Pure Chemical Industries, Osaka, Japan). RNA extraction and real-time RT-PCR by the universal probe library (Roche Molecular Biochemicals, Tokyo, Japan) were performed as previously described.
12) The PCR primer sequences for the rat peripheral leukocytes are listed in Table 1 . All data are expressed as the mean AE SEM. The significance of differences between groups was determined by Tukey's test, based on a one-way analysis of variance (ANOVA, Fig. 1 ) or based on a paired twoway analysis of covariance (ANCOVA, Fig. 2) . A level of p < 0:05 was considered to indicate statistical significance.
The blood glucose concentration immediately prior to the sucrose loading was approximately 190 mg/dL in all groups, and was markedly increased in the control group by the sucrose loading, with a maximum level of 275 AE 13 mg/dL being attained 30 min after sucrose loading. The blood glucose concentration in the animals given the sucrose solution with miglitol was significantly lower than that in the control group after 15 and 30 min (p < 0:05). The blood glucose concentration in the rats given the sucrose solution with anagliptin was significantly lower than that in the control group after 30 and 60 min (p < 0:05) (Fig. 1) . The mRNA levels of genes including IL-1, IL-18, TNF-, S100a8, S100a9, S100a11, interleukin-1 receptor 2 (IL-1R2), interleukin 1 receptor antagonist (IL-1Rn) and tumor necrosis factor receptor 2 (TNFR2) in the peripheral leukocytes were significantly higher after 180 min than the basal levels in the control group, but not in the miglitol or anagliptin groups. mRNA of interleukin-1 receptor 1 (IL-1R1), tumor necrosis factor receptor 1 (TNFR1) and interleukin 18 receptor 1 (IL18R1) did not change among the groups (data not shown). At 180 min after sucrose loading, the mRNA levels of the IL-1, IL-18, TNF-, S100a11, IL-1R2 and IL-1Rn genes were significantly lower in both drug groups than in the control group, with the mRNA level of the S100a8 gene being significantly lower in the miglitol group than in the control group. The mRNA level of the S100a9 gene was also significantly lower in the anagliptin group than in the control group (Fig. 2) .
We have demonstrated in this study that a single oral sucrose load administered to OLETF rats not only induced postprandial hyperglycemia, but also enhanced the expression of such inflammation-related genes as IL-1, IL-18, TNF-, S100 proteins, IL-1R2, IL-1Rn and TNFR2. It has been reported that S100 proteins, including S100a8 and S100a9, were intimately related to the pathogenesis of atherosclerosis by acting as cytokine/chemokine-like factors via binding to the receptor for advanced glycation end-products (RAGE) on leukocytes. 15, 16) IL-1R2 and TNFR2 are the respective receptors for IL-1 and TNF-. The results of this present study suggest that postprandial hyperglycemia was associated with the development and progression of CVD by enhancing the expression of inflammationrelated genes in peripheral leukocytes of an animal model of obesity and insulin resistance. As shown in our previous study, intermittent sucrose loading enhanced postprandial hyperglycemia and the expression of IL-1 and TNF-genes in peripheral leukocytes of low-dose STZ-treated rats, this being a model of reduced insulin secretion capacity. 12) Combining the results of the previous study with those of the current study, postprandial hyperglycemia induced the expression of IL-1 and TNF-genes in peripheral leukocytes of an animal model with either insulin secretion deficiency or insulin resistance. It should be noted that IL-1Rn was induced by a single oral sucrose load in peripheral leukocytes. Since IL-1Rn is an antagonist for IL-1, it is possible that a single oral sucrose load induced the antiinflammation step as a negative feedback system. It should be examined whether immediate sucrose loading alters the IL-1/IL-1Rn mRNA ratio in peripheral leukocytes of OLETF rats at the earlier and later stages of type 2 diabetes. In addition, it should be noted that the induction of IL-1, TNF-and IL-18 mRNAs by a single oral sucrose load was greater in OLETF rats used in this study than in STZ-induced moderate postprandial hyperglycemic rats in a previous study, 12) although the postprandial hyperglycemic levels without drugs were similar (the glucose level in OLETF rats after 30 min a IL-1β was 274:6 AE 13:0 mg/dL; that in STZ rats was 240:1 AE 6:4 mg/mL). STZ-treated rats are known as a model of insulin secretion deficiency by inducing the apoptosis of pancreatic -cells. On the other hand, OLETF rats are a model that exhibits obesity, in addition to the late onset of chronic and slowly progressive hyperinsulinemia, hyperglycemia and hyperlipidemia caused by overeating. 13) Recent studies have demonstrated that a metabolic abnormality with obesity and lipid abnormality, which is frequently called the metabolic syndrome, was more closely associated with the development of CVD than was a metabolic abnormality without obesity and lipid abnormality. 17, 18) The response to postprandial hyperglycemia of the inflammatory cytokine and S100s genes in peripheral leukocytes may therefore be enhanced by the obesity and lipid abnormality.
Interestingly, treating with either an insulin-dependent drug (anagliptin) or an insulin-independent drug (miglitol) reduced the oral-sucrose-inducible expression of the genes encoding inflammatory cytokines, S100 proteins and receptors for IL-1 and TNF-in peripheral leukocytes. These results strongly suggest that either an insulin-dependent or insulin-independent drug would enable suppression of the postprandial induction of these inflammation-related genes in peripheral leukocytes. Our previous study has demonstrated that a miglitol treatment for 20 d reduced the expression of IL-1, TNF-and S100 proteins in the peripheral leukocytes of STZ hyperglycemic rats. 19) Furthermore, the miglitol treatment for 40 weeks from the pre-diabetic stage (5-week-old) repressed the TNF-mRNA level in peripheral severe leukocytes. 20) Our previous studies have demonstrated in humans that reducing postprandial hyperglycemia by miglitol in Japanese type 2 diabetic patients for 3 months reduced the level of circulating TNF-protein and the mRNA level in peripheral leukocytes. 21) Whether a single dose of miglitol or anagliptin to OLETF rats at the earlier and later stages of type 2 diabetes and whether long-term treatment with miglitol or anagliptin can suppress the levels of mRNA in peripheral leukocytes and protein in the serum of inflammation-related genes in the peripheral leukocytes of OLETF rats needs to be examined.
It should be noted that insulin-dependent drugs, including DPP-4 inhibitors, could induce obesity, because insulin stimulates fatty acid synthesis. Indeed, a previous study has demonstrated that the -glucosidase inhibitor, acarbose, reduced body weight, whereas the DPP-4 inhibitor, vildagliptin, had little effect. 22) However, unlike -glucosidase inhibitors, DPP-4 inhibitors can suppress between-meal hyperglycemia. The combined use of an -glucosidase inhibitor and a DPP-4 inhibitor could therefore reduce postprandial and between-meal hyperglycemia and inhibit obesity. Further studies on animal models and type 2 diabetic patients should examine whether co-treating with an -glucosidase inhibitor and a DPP-4 inhibitor for a longer period of time could improve glycemic control and reduce body weight.
In conclusion, this study has demonstrated that acute postprandial hyperglycemia led to enhanced expression of the genes related to inflammation in peripheral leukocytes, and that inhibiting postprandial hyperglycemia by either anagliptin or miglitol reduced the expression of these genes.
